Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose

References

• Lin SY, Lin TL. Different types of direct compressible excipients affecting the release behavior of theophylline controlled-release tablets containing eudragit resins. Drug Dev Ind Pharm. 1993;19(13):1613–1621.
   Google Scholar
• Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Tech Prod Mfr. 1984;5:1–9.
   Web of Science ®Google Scholar
• Anurag S, Ramesh P. Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index. Int J Pharm. 2003;261(1–2):27–41.
   PubMedGoogle Scholar
• Najib N, Suleiman MS. The kinetics of drug release from ethylcellulose solid dispersions. Drug Dev Ind Pharm. 1985;11(12):2169–2181.
   Google Scholar
• Li CL, Martini LG, Ford JL, Roberts M. The use of hypromellose in oral drug delivery. J Pharm Pharmacol. 2005;57(5):533–546.
   PubMedGoogle Scholar
• Chattaraj SC, Das SK. Effect of formulation variables on dissolution profile of dictlofenac sodiumk sodium from ethyl- and hydroxylpropylmethyl cellulose tablets. Drug Dev Ind Pharm. 1996;22(7):555–559.
   Google Scholar
• Lütfi G, Esmaeil J. Preparation and in vitro evaluation of controlled release hydrophilic matrix tablets of ketorolac tromethamine using factorial design. Drug Dev Ind Pharm. 2008;34(8):903–910.
   PubMedGoogle Scholar
• Lee BJ, Ryu SG, Cui JH. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev Ind Pharm. 1999;25(4):493–501.
   PubMedGoogle Scholar
• Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS Pharm Sci Tech. 2003;4(3): article 31.
   PubMedGoogle Scholar
• Siahi MR, Jalali MB, Monajjemzadeh F, Ghaffari F, Azarmi S. Design and evaluation of 1- and 3-layer matrices of verapamil hydrochloride for sustaining its release. AAPS Pharm Sci Tech. 2005;6(4): article 77.
   PubMedGoogle Scholar
• Samani SM, Montaseri H, Kazemi A. The effect of polymer blends on release profiles of diclofenac sodium from matrices. Eur J Pharm Biopharm. 2003;55(3):351–355.
   PubMedGoogle Scholar
• Conte U, Meggi L. Multi-layer tablets as drug delivery devices: Geomatrix® technology. Pharm Technol Eur. 1998;1(2):18–25.
   Google Scholar
• Maggi L, Bruni R, Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int J Pharm. 2000;195(1–2):229–238.
   PubMedGoogle Scholar
• Weiss NT, Jones L, Chamberlain JC. A possible case of venlafaxine-induced Stevens-Johnson syndrome. J Clin Psychiatry. 2004;65(10):1431–1433.
   PubMedGoogle Scholar
• Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: A comparative analysis. Hum Psychopharmacol. 2004;19(1):9–16.
   PubMedGoogle Scholar
• Odidi I, Odidi A. 2003. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum. Assignee: Intellipharmaceutical Corp., Mississauga, CA. US Patent No.: 6,607,751; August 19, 2003.
   Google Scholar
• Odidi I, Odidi A. 2006. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum. Assignee: Intellipharmaceutical Corp., Mississauga, CA. US Patent No.: 7,090,867; August 15, 2006.
   Google Scholar
• Sherman DM, Clark J, Lamer JU, White SA. 2001. Extended release formulation of venlafaxine hydrochloride. Assignee: American Home Products Corp., Madison, NJ. US Patent No.: 6,274,171; August 14, 2001.
   Google Scholar
• Sherman DM, Clark J, Lamer JU, White SA. 2002. Extended release formulation of venlafaxine hydrochloride. Assignee: Wyeth, Madison, NJ. US Patent No.: 6,403,120; June 11, 2002.
   Google Scholar
• Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm. 2001;220(1–2):77–83.
   PubMed Web of Science ®Google Scholar
• Higuchi T. Mechanisms of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149.
   Google Scholar
• Ertan G, Karasulu HY, Karasulu E, Ege MA, Kose T, Guneri T. A new in vitro/in vivo kinetic correlation method for nitrofurantoin matrix tablet formulations. Drug Dev Ind Pharm. 2000;26(7):737–743.
   PubMedGoogle Scholar
• Langenbucher F. Linearization of dissolution rate curve by the Weibull distribution. J Pharm Pharmacol. 1972;24(12):979–981.
   PubMedGoogle Scholar
• Gohel MC, Parikh RK, Padshala MN, Sarvaiya KG, Jena DG. Formulation and optimization of directly compressible isoniazid modified release matrix tablet. Indian J Pharm Sci. 2007;69(5):640–645.
   Google Scholar
• Bamba M, Puisievx F, Marty JP, Carstensen, JT. Release mechanism in gel forming sustained release formulations. Int J Pharm. 1979;2:307–311.
   Web of Science ®Google Scholar
• Roy DS, Rohera BD. Comparative evaluation of rate of hydration and matrix erosion of HEC and HPC and study of drug release from their matrices. Eur J Pharm Sci. 2002;16(3):193–199.
   PubMedGoogle Scholar
• Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–896.
   PubMed Web of Science ®Google Scholar
• Kopcha M, Tojo KJ, Lordi NG. Evaluation of methodology for assessing release characteristics of thermosoftening vehicles. J Pharm Pharmacol. 1990;42:745–751.
   PubMed Web of Science ®Google Scholar
• Ratsimbazafy V, Bourret E, Brossard C. Drug release from matrix tablets and minitablets containing glycerides. Pharm Ind. 1996;58:442–446.
   Web of Science ®Google Scholar
• United State Phamacopeia, National Formulary (USP 29, NF24). Powder flow (1174). The United States Pharmacopeial Convention, Rockville, MD; 2006;3017–3020.
   Google Scholar
• Tiwari SD, Rajabi-Siahboomi AR. Modulation of drug release from hydrophilic matrices. Pharm Tech Asia Pacific. 2008;2 (3):20–25.
   Google Scholar
• Dias VD. Modulation of drug release from hypromellose (HPMC) matrices: Suppression of the initial burst effect. At the American association of Pharmaceutical Scientists Annual Meeting and Exposition, San Antonio, TX, USA; 2006.
   Google Scholar
• Dias VD, Gothoskar AV, Rajabi-Siahboomi AR. Investigation of a venlafaxine HCl (37.5mg) extended release formulation using hypromellose (HPMC) matrices, 2006. Accessed 18 September 2008 from the website: http://www.colorcon.com.
   Google Scholar
• Dokoumetzidis A, Papadopoulou V, Macheras P. Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function. Pharm Res. 2006;23:256–261.
   PubMed Web of Science ®Google Scholar
• Conte U, Meggi L, Colombo P, La MA. Multilayered hydrophilic matrices as constant release devices (Geomatrix™ Systems). J Control Rel. 1993;26:39–47.
   Web of Science ®Google Scholar
• El-Nabarawi MA. Modulation of tenoxicam release from hydrophilic matrix: Modulator membrane versus rate-controlling membrane. Chem Pharm Bull. 2005;53(9):1083–1087.
   PubMedGoogle Scholar
• FDA Alert for Healthcare Professionals. July 2005. Hydromorphone Hydrochloride Extended-Release Capsules (marketed as Palladone™). Accessed 8 March 2008 from the website: http://www.fda.gov/cder/drug/InfoSheets/HCP/hydromorphoneHCP.pdf, part of http://www.fda.gov.
   Google Scholar
• Traynor MJ, Brown MB, Pannala A, Beck P, Martin GP. Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments. Drug Dev Ind Pharm. 2008;34(8):885–889.
   PubMedGoogle Scholar
• Rowe RC, Sheskey PJ, Weller PJ. Ethyl cellulose. In: Handbook of excipients. 4th ed. PhP Pharmaceutical Press; 2003;237–241.
   Google Scholar
• Lu Z, Chen W, Olivier E, Hamman JH. Matrix polymer excipients: Comparing a novel interpolyelectrolyte complex with hydroxypropylmethylcellulose. Drug Deliv. 2008;15:87–96.
   PubMed Web of Science ®Google Scholar